Oric Pharmaceuticals (ORIC) Accumulated Depreciation (2019 - 2026)

Oric Pharmaceuticals' Accumulated Depreciation history runs 8 years deep, the most recent figure standing at $7.9 million for Q1 2026.

• Quarterly Accumulated Depreciation rose 1.86% year-over-year to $7.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $7.9 million (up 1.86% YoY) and the FY2025 annual result came in at $7.7 million, up 2.34% from the prior year.
• Accumulated Depreciation was $7.9 million for Q1 2026 at Oric Pharmaceuticals, up from $7.7 million in the prior quarter.
• Across five years, Accumulated Depreciation topped out at $8.2 million in Q3 2025 and bottomed at $5.2 million in Q1 2022.
• A 5-year average of $6.8 million and a median of $6.7 million in 2024 frame the typical range for Accumulated Depreciation.
• Annual changes were most pronounced in 2025 — Accumulated Depreciation grew 16.62% — and 2026, when it rose 1.86%.
• Oric Pharmaceuticals' Accumulated Depreciation stood at $5.8 million in 2022, then rose by 12.1% to $6.5 million in 2023, then climbed by 15.12% to $7.5 million in 2024, then advanced by 2.34% to $7.7 million in 2025, then climbed by 3.53% to $7.9 million in 2026.
• Business Quant data shows ORIC's Accumulated Depreciation at $7.9 million in Q1 2026, $7.7 million in Q4 2025, and $8.2 million in Q3 2025.